FINWIRES · TerminalLIVE
FINWIRES

Cleo Diagnostics Enters Analytical Validation Phase for Ovarian Cancer Blood Test; Shares Fall 6%

By

Cleo Diagnostics (ASX:COV) entered the analytical validation phase for its blood test for the early and accurate detection of ovarian cancer, according to a Monday Australian bourse filing.

The company completed the final development and preparation activities required for the phase, including commercial assay development as well as the completion of patient recruitment and prospective blood sample collection for its pivotal US clinical trial.

Analytical validation is expected to start in August upon receipt of the first manufactured batch of its test kits from Bio-Techne, per the filing. The company will evaluate three independently manufactured production batches to demonstrate assay reproducibility, manufacturing consistency, and overall analytical robustness.

The company said it expects analytical validation to take around four months to complete, adding that it anticipates US Food and Drug Administration submission to occur in the first half of 2027.

Cleo Diagnostics' shares fell nearly 6% in recent trading on Monday.

Related Articles

Asia

Claimants Withdraw Lawsuit Against PropNex's Arm

PropNex (SGX:OYY) said a lawsuit filed against the company's wholly-owned subsidiary, PropNex Realty, as a co-defendant, has been dropped, according to a Friday filing to the Singapore stock exchange.The claimants have discontinued and withdrawn the suit, the statement said.PropNex Realty was named as one of three co-defendants in a lawsuit filed in the High Court of Singapore in February. According to the lawsuit, claimants sought damages against PropNex Realty for alleged breach of duty of care and sought compensation of around SG$367,405 in damages.The withdrawal of the case is not expected to have any material impact on the financial position and performance of the group for the financial year ending Dec. 31.PropNex's shares were down nearly 1% in Monday's trade.

SGX:OYY
Asia

Dawning Information Industry Proposes Convertible Bond Issue for AI, Storage Push

Dawning Information Industry (SHA:603019) on Monday filed a prospectus for a convertible bond issue to unspecified investors.Proceeds are earmarked toward an artificial intelligence computing cluster system, a next-generation AI training-inference integrated machine and a domestic advanced storage system.Shares of the supercomputer manufacturer were down 1% in recent trade.

SHA:603019
Asia

Ampol Secures KKR as Cornerstone Investor in AU$400 Million Financing Transaction; Shares Up 3%

Ampol (ASX:ALD) secured a cornerstone investment from KKR in its AU$400 million financing transaction, according to a Monday statement from the investment firm.KKR is making this investment from its Asia Pacific Credit strategy and insurance platform, with support from Clifford Capital.Ampol will use the funds for refinancing initiatives and other general corporate purposes.Ampol's shares rose nearly 3% in recent trading on Monday.

ASX:ALD